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The Inhalation Toxicology Research Institute (ITRI) is conducting research to improve the under-
standing of chronic beryllium disease (CBD) and beryllium-induced lung cancer. Initial animal
studies examined beagle dogs that inhaled BeO calcined at either 500 or 1000°C. At similar lung
burdens, the 500°C BeO induced more severe and extensive granulomatous pneumonia, lympho-
cytic infiltration into the lung, and positive Be-specific lymphocyte proliferative responses in vitro
than the 1000°C BeO. However, the progressive nature of human CBD was not duplicated. More
recently, Strains A/J and C3H/HeJ mice were exposed to Be metal by inhalation. This produced a
marked granulomatous pneumonia, diffuse infiltrates, and multifocal aggregates of interstitial
lymphocytes with a pronounced T helper component and pulmonary in situ lymphocyte prolifera-
tion. With respect to lung cancer, at a mean lung burden as low as 17 pg Be/g lung, inhaled Be
metal induced benign and/or malignant lung tumors in over 50% of male and female F344 rats
surviving 2 1 year on study. Substantial tumor multiplicity was found, but K-ras and p53 gene
mutations were virtually absent. In mice, however, a lung burden of approximately 60 pg (-300
pg Be/g lung) caused only a slight increase in crude lung tumor incidence and multiplicity over
controls in strain A/J mice and no elevated incidence in strain C3H mice. Taken together, this
research program constitutes a coordinated effort to understand beryllium-induced lung disease
in experimental animal models. Environ Health Perspect 104(Suppl 5):973-979 (1996)
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proliferation, cancer
Introduction
The toxicity of beryllium (Be) and its
compounds has been a topic ofconcern for
some 60 years, even though earlier reports
dealt with this issue (1). Concerns were
largely driven by reports of Be-induced
toxicity in humans in Europe in the 1930s
and in the United States in the 1940s (2).
After approximately 1950, the acute form
of Be-induced lung disease was largely
eliminated due to the establishment of
workplace exposure limits, but the chronic
form of the disease is still of concern.
Chronic beryllium disease (CBD) is char-
acterized by progressive, noncaseating
granulomatous inflammation of the lung
that may be fatal. CBD occurs in only
approximately 3% of exposed individuals
and it has been suggested that a genetic
predisposition is involved (3).
Numerous animal models of Be-
induced toxicity were investigated in the
1940s, despite a 1943 report by the U.S.
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Public Health Service (4) that erroneously
exonerated Be as the causative toxic agent.
The early work was brought together in
1947 with the Sixth Saranac Symposium
(5), a galvanizing meeting for investigators
dealing with industrial hygienic and
toxicologic concerns for Be.
Over the subsequent decades, numer-
ous reports were published from animal
experiments involving Be exposures. These
include the production of pneumonitis in
animals inhaling Be compounds compara-
ble to that seen in humans, the induction
of osteosarcomas in rabbits injected with
beryllium oxide (BeO) and zinc Be silicate
(6), the production oflung tumors in rats
inhaling beryllium sulfate (BeSO4) (7),
and the characterization of differing
immune responses in two strains of guinea
pigs (8). A full review of this work is
beyond the scope of this article; other
recent reviews and summaries ofthe litera-
ture describing the health effects (9-11)
and biokinetics (12) are available.
This article provides an overview of
studies ofthe inhalation toxicity ofBe con-
ducted at the Inhalation Toxicology
Research Institute (ITRI). These studies,
which began in 1982, are described below.
Studies at the Inhalation
Toxicology Research Institute
The ITRI is conducting research to
improve the understanding ofCBD and to
examine Be-induced lung cancer. Central
to these efforts have been field studies of
Be-containing aerosols likely to be found
in the workplace, development oflabora-
tory model aerosols mimicking workplace
aerosols, detailed physicochemical charac-
terization of these materials, and use of
these aerosols in laboratory animal models.
The following sections describe aerosol
and physicochemical studies, efforts to
develop an animal model having the key
features of human CBD, and studies of
Be-induced carcinogenesis.
Aerosol andPhysicochemical Studies
Initial ITRI studies focused on proposed
uses of Be as a plasma limiter in fusion
devices and soon expanded to include the
potential uses of Be in structural, naviga-
tional, and nuclear reactor systems for
space. Beryllium aerosols formed under
industrial and applied research conditions
were collected and examined (13); materials
included machining-generated Be metal
and BeO aerosols, stock Be metal and BeO
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powders, and aerosols derived from elec-
tron or laser beam impaction on Be blocks,
and Be particles from a research fusion
device. Particles of respirable size were
found in all cases; particle morphology
ranged from branched-chain aggregates in
the case of laser vaporization to irregular
shapes produced by the other operations.
Additional efforts were made to character-
ize aerosols produced by the machining of
Be metal, BeCu, or BeNi alloys; for a given
machining operation, a greater percentage
of the Be metal aerosol was found in the
respirable size fraction than in either alloy
(14). During this period of extensive
aerosol development, an overview for prac-
ticing engineers was also prepared on the
history of Be dispersion, regulations and
industrial hygiene practices related to Be,
and perspectives on the health risks of
using Be (15).
Efforts were begun to mimic these
workplace and research aerosols with
appropriate surrogate aerosols produced
under well-controlled laboratory conditions.
Model aerosols for a radioisotope-labeled
7BeO generated from the nebulization ofa
7Be(OH)2 suspension and calcined at
either 500 or 1000GC were developed
(16). A laboratory laser vaporization tech-
nique capable of generating branched-
chain aggregate aerosols of either Be metal
(when operated under an argon atmos-
phere) or BeO (when operated under air)
was also developed (17). Finally, a method
employing dry-powder aerosolization with
size fractionation using an aerosol cyclone
was developed for an industrial preparation
ofBe metal powder (18).
An extensive quality control program
was begun to certify and compare the
chemical and physical properties ofthe lab-
oratory aerosols. This program involved
determination of particle morphology and
geometric size, aerodynamic size, specific
surface area, density, dissolution character-
istics, chemical form, crystallinity, and
composition (19-21). The work was com-
plemented with in vitro toxicity studies in
cell cultures in which for a given Be com-
pound, short-term toxicity appeared to be
governed by the amount ofspecific surface
area of the preparation, and thus presum-
ably the surface available for dissolution of
Be ions (22).
Important features of these laboratory
model aerosols include the production of
particle sizes ranging from several tenths to
2 pm in mass median aerodynamic size,
thus making the aerosols ofoptimal size for
deposition in the alveolar compartment of
Table 1. Experimental design for study of beagle dogs exposed to BeO calcined at 500 or 10000C.a
Mean lung burden achieved and BeO calcination temperature
Sacrifice time 17 pg BeO/kgd 50 pg BeO/kgd
(days after exposure)" Controlsc 5000C 1000C 5000C 1000°C
8 - 2e 2 - _
32 - 2 2 - -
64 - 2 2 - -
180 - 2 2 2 2
360 - 2 2 2 2
-1100 4 4 4 4 4
aDogs sacrificed from 8 to 360 days after exposure to examine biokinetics and histopathologic effects of BeO.
Dogs sacrificed at approximately 1100 days after exposure were reexposed to 500°C BeO (mean initial lung burden
of 74 pg BeO/kg) at approximately 900 days after first exposure and were used to examine the immunopathologic
effects of BeO. Additional details have been published (25,26,28). bSingle, acute, nose-only inhalation exposure.
cControl dogs were sham-exposed to filtered air only. dFor each BeO preparation temperature, mean lung burden
(after completion of rapid clearance phase of BeO deposited on conducting airways) normalized by body weight at
time of exposure for each dog. eNumber of dogs per group; equal numbers of males and females. A dash (-)
indicates no dogs exposed at the indicated conditions.
the lung; thorough physical and chemical
characterization, as described above; and
ability to generate exposure atmospheres
over a wide range of concentrations, thus
permitting a wide range oflung burdens to
be delivered in relatively short times. This
latter point is particularly true for Be
metal; the aerosolization system for this
material can provide mass concentrations
ranging from several tenths ofmg/m3 up to




Studies in Dogs. Studies of Be-induced
granulomatous lung disease began with an
examination of the toxicokinetics of 500
and 1000GC BeO in the beagle dog. An
associated goal was the possible develop-
ment of a CBD model. Justification for
this approach included the clear indication
from the literature of the importance of
BeO preparation temperature on Be dispo-
sition and toxicity following inhalation
(23), and the need for biokinetic data
describing the disposition of these two
BeO preparations. The beagle dog was
selected because it represents a good bioki-
netic model for the disposition of other
important elements (24), is amenable for
the collection of toxicokinetic data and
monitoring of pulmonary responses (using
periodic radiographs and intrapulmonary
lavage), and has immunological responses
similar to those ofhumans (25).
A dose-response pilot study in dogs
using BeO treated during generation at
500°C indicated that granulomatous lung
lesions were present 1 month after expo-
sure (26). Additional dogs were subse-
quently exposed by inhalation to 7BeO
that had been treated at 500°C during
generation and subsequently calcined at
either 500 or 1000°C. Dogs received mean
lung burdens ofeither 17 or 50 pg/kg body
weight; control dogs received a sham
exposure (experimental design given in
Table 1). Groups ofdogs (2 dogs per time
point per calcination temperature per lung
burden level) were sacrificed at various
times through 1 year after exposure (a total
of28 dogs) to measure 7Be content in vari-
ous tissues (27), and to evaluate lung and
lung-associated lymph node lesions (28).
Another group of dogs was held for peri-
odic assessment as described below. As
expected, the BeO prepared at 500°C was
cleared from the lung more rapidly than
the 1000°C material (clearance half-times
of 72 and 210 days, respectively).
Beryllium cleared from the lung was either
excreted (principally in feces at early times
after exposure, later in urine) or translo-
cated primarily to bone and liver. Through
1 year after exposure, lung lesions observed
included macrophage hyperplasia, granulo-
mas, fibrosis, alveolar epithelial cell hyper-
plasia, and lymphocytic infiltrates. These
lesions were generally more extensive or
severe in dogs exposed to the 500°C BeO,
and peaked in relative severity at 2 months
after exposure.
Twenty dogs (4 controls and 4 each per
calcination temperature per lung burden)
were not sacrificed, but were followed by
periodic radiography and collection ofblood
and intrapulmonary lavage fluids for assess-
ment of cell types and performance of
standard in vitro lymphocyte proliferation
assays (LPA) to detect Be-specific immune
responses (28). In blood, positive LPA
results were observed only sporadically in all
exposure groups. Lymphocytes constituted
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over 50% of lung lavage cells 3 months
after exposure in a group of four dogs
inhaling 500°C BeO, then percentages
declined to less than 30% by 7 months
after exposure. The positive LPA results
observed were most prominent in dogs that
inhaled the 5000C BeO to achieve the 50
pg/kg lung burden. These results generally
peaked 6 to 8 months after exposure, then
declined. There was substantial variability
among individual dogs, and an apparent
shift toward more T-helper lymphocytes
when lymphocyte numbers were elevated
relative to controls. Additional work using
cloned lung lymphocyte T-cell lines sug-
gested a Be-specific, major histocompatibil-
ity complex Class-II-mediated nature of
the response (29).
Continued monitoring of the dogs
through 2 years after exposure, however,
coupled with the Be lung clearance data
and the decrease in the relative severity of
lung toxicity from 2 months to 1 year in
the sacrificed dogs, suggested that toxic
reactions to Be had largely resolved. Thus,
although these results were promising, a
model of the progressive nature of CBD
was not developed. To determine ifpoten-
tial immune memory of Be might result in
responses greater in either magnitude or
duration than seen after the first exposure,
the dogs were reexposed by inhalation to
500°C BeO approximately 2.5 years after
their first exposure to result in a mean lung
burden of 74 pg/kg (30). The influx of
lymphocytes, reactivity of the lymphocytes
as revealed by the LPA, and lung lesions
upon sacrifice 6 months after exposure
were similar to those seen after the first
exposure, indicating that these responses
did not appear to be cumulative using this
exposure regime.
Studies in Cynomolgus Monkeys. To
refine and extend these observations in
dogs, the immunopathologic responses to
Be were examined in cynomolgus mon-
keys (Macacafascicularis). One important
reason to extend these studies to nonhu-
man primates was the lack at that time of
appropriate antibodies against the various
T-lymphocyte subpopulations in the dog.
The monkeys were exposed by broncho-
scopic, intrabronchiolar instillation to
either BeO calcined at 500°C or to Be
metal (31). A separate lung lobe received
an instillation of the saline vehicle alone.
The masses of Be used ranged from 0.4 to
38 pg for the BeO, and 1.0 to 148 pg for
the Be metal; the differing amounts were
used because they were estimated to pro-
vide roughly equimolar amounts of the
Be++ ion dissolved from the particles over
the 6-month study.
The monkeys underwent bronchoalveo-
lar lavage at various times after instillation.
The animals were sacrificed at either 80 or
180 days after exposure for evaluation of
lung histopathology. Compared to control
lung lobes, the numbers oflymphocytes
obtained from exposed lobes were elevated at
14, 30, and 90 days postexposure (dpe) in
the Be metal-exposed animals, and at 60 dpe
in the BeO-exposed monkeys. Be-specific in
vitro lymphocyte proliferation occurred at
14, 60, and 90 dpe in lymphocytes from Be-
exposed lung lobes only; no Be-specific lym-
phocyte proliferation was observed in
BeO-exposed animals. Lung lesions in Be
metal-exposed monkeys included focally
intense, interstitial fibrosis, marked hyperpla-
sia ofthe alveolar epithelium, and variable
lymphocytic infiltrates. Some Be metal-
exposed animals had discrete immune gran-
ulomas characterized by tightly organized
lymphocytic cuffs surrounding epithelioid
macrophage aggregates. When present,
lesions in BeO-exposed monkeys were rare
and much less severe.
Thus, lung lesions having certain
features of CBD were successfully pro-
duced in the cynomolgus monkey and
were accompanied by Be-specific immune
responses. Furthermore, the results sug-
gested that Be metal produced more severe
lesions than the BeO prepared at 500°C.
However, the experimental design pre-
cluded an examination ofwhether the pul-
monary responses increased over time or
resolved, as was observed in the dogs.
Largely because of the expense ofworking
with the nonhuman primates and the
related inability to study more than a few
individuals, this line of investigation was
not pursued.
Studies in Rodents. To determine if
mice that inhaled Be develop responses
that mimic human CBD, female strains
A/J and C3H/HeJ mice were exposed to a
Be-metal aerosol to achieve mean initial
lung burdens of 47 pg or 64 pg, respec-
tively (32). The mice were sacrificed 28
weeks after exposure. Cells were harvested
from peripheral blood, spleen, and
bronchial lymph nodes of both exposed
and control mice. Be-specific in vitro lym-
phocyte proliferation was assayed, but
responses were seen only in the positive
control samples in which the lymphocytes
were exposed to phytohemagglutinin.
The right cardiac lunglobes from selected
mice were inflated with a cryopreservative
agent, frozen, then sections were cut and
reacted with antibodies to detect mouse B,
helper T, and suppressor T lymphocytes.
Remaining lung lobes were fixed and sec-
tioned for standard histopathology; this
examination revealed a marked, multifocal,
granulomatous pneumonia with mild
interstitial fibrosis, perivascular and inter-
stitial mononuclear (lymphocytes, plasma
cells, monocytes, and macrophages) cell
infiltrates, and multifocal interstitial mono-
nuclear cell aggregates. Multinucleated
giant cells were common; most were ofthe
foreign-body type, but Langhans giant cells
were also found. Immunohistochemical
examination showed that these interstitial
mononuclear cell aggregates were of two
types: some consisted primarily ofhelper T
cells and Be-containing macrophages
(microgranulomas), while others consisted
ofa central zone ofB cells and a peripheral
zone of helper T cells. Helper T cells,
which were the majority oflymphocytes in
the lungs ofBe-exposed mice, were located
in the aggregates described above, in the
interstitium within foci ofgranulomatous
inflammation, and in perivascular cuffs.
Suppressor (CD8+) T cells were infrequent
and scattered within the lesions.
A subgroup of the mice received
injections of a 5-bromo-2-deoxyuridine
(BrdU) solution 2 days to 1 hr before
sacrifice to label the nuclei of replicating
cells. This treatment revealed lymphocyte
proliferation within microgranulomas,
perivascular cuffs, and the lymphoid aggre-
gates. Unfortunately, because different
groups of mice received lung cryosection
immunohistochemistry and the BrdU
labeling, the BrdU technique could not
permit the identification ofeither the pro-
liferating lymphocyte subtype or Be
specificity ofthe response.
No substantive differences in response
between the two murine strains were
observed; other strains have not been
examined. The observed chronic lung
lesions parallel those seen in human CBD
cases in several important respects: morpho-
logically, with the helper T cells constitut-
ing the primary lymphocytic componenit,
and proliferatively, with the pronounced in
situ lymphocyte replication (Table 2).
However, the Be specificity of these
responses must be demonstrated before the
disease in mice can be considered an ani-
mal model ofhuman CBD. Efforts in this
area continue.
Studies ofBe-induced Cancer
Studies in Rats. Studies of Be metal-
induced cancer began at ITRI as part of a
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Table 2. Comparison of responses between human chronic beryllium disease cases and strains A/J and C3H/HeJ
mice inhaling beryllium metal.a
Responseb Humans Mice
Microgranulomas/mononuclear infiltrates + +
Significant lymphocytic component + +
Accumulation of helper T cells + +
Lymphocyte proliferation
In vivo +/? +
Be-specific in vitro + -/?
Delayed hypersensitivity + ?
aTwo strains of mice received a single, acute, nose-only inhalation exposure to result in mean initial lung burdens
of 47 pg (for strain A/J) or 64 pg (for strain C3H) Be metal; experiment described in text. bKey to responses: + =
response observed; +/? = response probably occurs but has not been definitively proven;-,? = response not
observed but a systematic examination ofthe response was not performed; ? = existence of response not known.
larger program to study the cancer risks
from exposures to combinations of radia-
tion and other agents. Pertinent to this
article, a study is being conducted in rats
exposed to Be metal and/or plutonium
dioxide (239PuO2) (33,34). The following
discussion relates primarily to rats exposed
only to Be metal within the larger study;
the Be portion ofthe design ofthis study is
given in Table 3.
Groups of F344/N rats (raised in the
ITRI barrier facility) were designated for
single, nose-only exposure to Be metal to
result in lung burdens ofapproximately 50,
150, or 450 pg. This involved exposures of
10 to 41 min to Be metal mass concentra-
tions of 470 to 960 mg/m3. Control rats
received filtered air alone. Following expo-
sure, groups ofrats were designated for ser-
ial sacrifice at times ranging from 8 to 450
dpe for determination ofthe quantity ofBe
within the lungs and for assessment of
presence or progression oflung lesions.
Exposure to the highest level of Be
metal (target lung burden of 450 pg)
proved acutely lethal to a substantial frac-
tion of the rats (35). Thirty-seven percent
of male and 49% of female rats died
approximately 2 weeks after exposure. The
lungs ofthese rats were characterized by a
severe hemorrhagic pneumonia (36). This
acute mortality was not observed in rats
exposed to lower lung burdens ofBe metal.
Inhaled Be metal also decreased long-term
survival in a dose-dependent manner (37).
For both genders, median survival times of
Be metal-exposed rats were similar to those
ofcontrols in groups receiving the lowest
target lung burdens, and were approxi-
mately 80% those ofcontrols at the highest
lung burdens.
Another effect observed in this com-
bined exposure study was a striking reduc-
tion in the lung's ability to clear Be and
other materials (33,37). Clearance of239Pu
from the lung in rats also inhaling Be metal
was best modeled by a single-component,
negative exponential function having a half-
time ofsome 500 days. This effectwas inde-
pendent ofthe level ofBe metal examined.
In contrast, 239Pu clearance in rats not also
exposed to Be was best modeled by a two-
component, negative exponential, and the
clearance half-time for the first component
(which accounted for approximately 80%
of the 239Pu lung burden) was about 35
days. For a given level of239PuO2 exposure,
the coexposure to Be metal with the associ-
ated reduction in lung 239Pu clearance
served to increase the total potential life-
span radiation dose to the lung by a factor
ofapproximately three, compared to con-
trols. This phenomenon has subsequently
been examined in more detail (below).
The most notable result from this study
was the carcinogenicity of Be metal to the
lungs of the F344/N rats; these data have
been reported in abstract form (38,39).
The most prevalent neoplasm observed was
the bronchiolar/alveolar adenocarcinoma
having alveolar, papillary, or tubular pat-
terns. Other tumors observed included
adenosquamous carcinomas and squamous
cell carcinomas. In addition, substantial
multiplicity of lung tumors within the
same animal was observed.
In four groups of 30 male and 30
female rats each receiving mean Be metal
initial lung burdens of40, 110, 360, and
430 pg Be, tumors became apparent by 14
months after exposure, and a crude inci-
dence of 64% of the rats developed lung
tumors over their lifetimes (40). An analy-
sis in the Be-induced rat lung adenocarci-
nomas of genes frequently mutated in
human lung cancers (the oncogenes K-ras
and c-raf-1, and the tumor suppressor gene
p53) revealed few alterations. Direct
sequencing ofexons 1 and 2 in 24 tumors
did not reveal any mutations in K-ras
codons 12, 13, or 61. A more sensitive
technique revealed codon 12 base pair
transversions in 2 of 12 tumors examined,
suggesting K-ras oncogene activation was a
rare, late event in the carcinogenic process.
No p53 gene mutations were observed
through either immunohistochemical tech-
niques or direct sequencing of exons 5
through 8, nor were c-raf1 mutations evi-
dent by Southern blot analysis. Thus, the
mechanisms underlying the production of
pulmonary adenocarcinomas from inhaled
beryllium in the rat do not involve gene
dysfunctions common with human non-
small-cell lung cancer.
As a result ofthe level ofcarcinogenicity
observed in this study, additional rats
(CDF(F344)/CrlBR, Charles River
Laboratories, Raleigh, NC) have been
exposed to lower lung burdens ofBe metal
(Table 3) and are being observed. Target
initial lung burdens for this portion of the
study range from 0.3 to 50 pg. The goal of
this work is to define dose-response rela-
tionships between lower lung burdens of
Table 3. Experimental design for study of Be metal carcinogenicity in F344 rats.a
Planned initial lung burden Rats exposed (no.)
of Be metal(pg)b Study Phase Study Phase 11 Total rats (no.)
0 208C 270 478
0.3 - 288 288
1.0 - 288 288
3.0 - 288 288
10 - 288 288
50 240 156 396
150 240 - 240
450 240 - 240
Total 928 1578 2506
"As described in the text, this is a part of a larger study of the carcinogenicity of combined exposures of rats to Be
metal and 239Pu02; this table describes the portion of the study in which rats receive no radiation treatment.
bPlanned level of initial lung burden resulting from a single, acute, nose-only inhalation exposure to Be metal.
cNumber of animals per group; equal numbers of male and female rats. A dash (-) indicates no rats exposed at the
indicated conditions.
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Be metal and lung cancer and to reproduce
in F344/Crl rats the findings described
above in F344/N rats.
Studies in Mice. The carcinogenicity
of inhaled Be metal is being examined in
two strains of mice: A/J mice, which are
susceptible to either spontaneous or chemi-
cally induced lung cancer, and C3H/HeJ
mice, a strain that is relatively resistant to
lung cancer induction (41). Groups of
mice were exposed to Be metal to result in
group mean initial lung burdens of47 pg
Be (A/J) or 64 jig Be (C3H). Serial sacri-
fices were conducted to yield lung tissue
for histologic examination, molecular
analysis of gene changes in the carcino-
genic process, and analysis of Be for
dosimetry and lung clearance data.
Histopathological analyses of the lungs
have been completed (42). Compared to
control mice, the crude incidence of lung
tumors in Be metal-exposed A/J mice is
slightly elevated (46% in exposed vs 37%
in controls) and in C3H/HeJ is slightly
decreased (5% in exposed mice vs 10% in
controls). In addition, tumor multiplicity
is slightly increased in the exposed A/J
mice compared to that in controls. The
potential statistical significance of these
data and the multiplicity and time-to-
tumor data are being analyzed. Be exposure
reduced survival for both strains. In a log-
rank test (Breslow test; SAS PIL, SAS
Institute, Cary, NC), this reduction in sur-
vival was statistically significant for strain
C3H mice (p=0.042) but only marginally
significant for strain A/J mice (p= 0.077).
Both exposed and control strain A/J mice
appeared to have slightly greater survival
times than C3H mice; however, neither
of these differences were statistically
significant (p>0.05).
An additional topic ofongoing analysis
in this study is the potential for mutations
in the K-ras oncogene (43). Preliminary
data suggest that K-ras gene mutations are
more common in the mouse lung tumors
than in the rat lung tumors, but muta-
tional hotspots are lacking within the gene,
which suggests that Be is not acting as a
genotoxic carcinogen.
Studies of Acute and Chronic
Inflammatory Lung Disease in Rats and
Mice. In concert with the cancer studies
in rats and mice described above, the
nature of acute and chronic responses to
inhaled Be metal have been examined
through 1 year after exposure in both
species. Male F344/N rats were exposed to
Be metal to result in lung burdens ranging
from 0.32 to 100 pg (about 0.2-85 pg
Be/g lung tissue), then sacrificed at 8, 16,
40, 90, 210, and 365 dpe (44). The Be
metal aerosol was mixed with an aerosol of
85Sr-labeled fused aluminosilicate particles
(85Sr-FAPs), a relatively insoluble particle
used as a tracer particle to study clearance
from the lungs. Control rats received the
85Sr-FAPs alone. Be exposure significantly
retarded 85Sr-FAP lung clearance in all
exposure groups, except for the lowest lung
burden (0.32 pg) where clearance was
slightly retarded but not statistically differ-
ent from that in controls. In addition, lung
burdens of 10 or 100 pg Be induced mini-
mal to mild acute and chronic inflamma-
tion, hyperplasia ofthe alveolar epithelium,
and early-occurring fibrosis, whereas a lung
burden of 1.8 pg caused only late-occur-
ring, minimal chronic inflammation and
alveolar epithelial hyperplasia. The histo-
logical changes were generally accompanied
by alterations in the enzyme, protein, and
cellular components of bronchoalveolar
lavage fluids.
A virtually identical study was also
performed in female C3H/HeJ mice (45).
Mice received both 85Sr-FAP tracer parti-
cles and Be metal lung burdens of 1.7 to
34 pg (about 14-280 pg Be/g lung). A
lung burden of 1.7 jig Be had some mea-
surable but minimal effect on lung clear-
ance, the 2.6-pg Be lung burden was
intermediate in effect, and lung burdens of
12 or 34 pg Be induced a substantial
reduction in pulmonary clearance of the
85Sr-FAP. Histological evaluation of the
lungs revealed granulomatous pneumonia
at later times, an increased number and size










interstitial infiltration of mononuclear
cells. Findings were most pronounced in
the two highest lung burden groups,
although a minimal granulomatous pneu-
monia was observed in many ofthe mice in
the 2.6-pg lung burden group. As with the
rats, indications oflung damage revealed
by bronchoalveolar lavage generally mir-
rored the lung histology results.
These studies in rats and mice provide
dose-response data describing the effects of
inhaled Be metal on lung toxicity. The
most striking difference in lung pathology
between the two species is the marked
component of interstitial lymphocytic
aggregates in the mouse; lymphocytes are
not a substantial component of the
response in rats. A comparison between the
two species is shown in Figure 1, in which
Be metal lung burdens are divided by con-
trol animal lung weight in an attempt to
normalize the data for comparison.
Another important difference between the
species appears to be the levels of Be lung
burdens required to induce a toxic reaction
in the lung; the rats are affected by the var-
ious changes described above at weight-
normalized lung burdens substantially
lower than those in mice.
Discussion
As noted in the introduction, a substantial
body of toxicity studies of Be in animals
exists (9-11). It can be difficult, however,
to comprehend the effects ofBe in animals
from this work. Many ofthe studies, partic-
ularly the early ones, are plagued by prob-
lems such as confounding diseases within





Rats - + +
Mice
0.1
+ + + ++ +
++ + +
10 100 1000
Be lung burden (jig Be/g lung weight)
Figure 1. Comparative responses of rats and mice following single, acute, nose-only inhalation exposure to beryl-
lium metal to result in a range of initial lung burdens. Symbols: (+), response observed; (±), response minor or
equivocal; (-), response not observed; (?), potential response currently being studied.
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modes of exposure; failure to quantitate
dose or disposition; or use of exposure
materials that were poorly characterized,
poorly described, or irrelevant to workplace
exposures (9).
Our studies of granulomatous lung
disease indicate that dogs and monkeys
respond to Be with many ofthe responses
seen in human CBD patients. These
responses include granulomatous lung
lesions having a significant lymphocytic
component, and the presence of in vitro,
Be-specific lymphocyte proliferative capa-
bility (46,47). However, the finding in
dogs that both of these responses resolve
indicates that a true, progressive model of
CBD has not been achieved following the
acute exposure modes used. In addition,
further work with dogs and monkeys is not
promising because of the substantial
expense associated with working with these
large-animal models and the related inabil-
ity to examine the large numbers of sub-
jects necessary with these outbred species.
The potential for developing useful models
of beryllium disease in rodents appears
much more promising.
Work with F344 rats indicates that the
lack ofsignificant lymphocytic response to
inhaled Be metal in this species renders it
unsuitable for detailed immunopathogenic
study (46). In mice, however, several paral-
lels between murine and human responses
were observed, most notably including the
development ofgranulomas and/or mono-
nuclear infiltrates having a pronounced
helper T cell component (Table 2). Efforts
continue to demonstrate Be-specific lym-
phoproliferative and delayed hypersensi-
tivity responses in the mouse. This work is
based on the premise that the development
of a laboratory animal model having the
significant features of human CBD will
afford opportunities to study not only the
cellular and molecular mechanisms of
responses involved in the progression of
CBD but also to examine both the influ-
ence of the physicochemical form of Be
and the exposure mode (single, chronic,
multiple) on disease outcome and the
potential for therapeutic intervention.
Studies of the carcinogenicity of
inhaled Be metal are being conducted in
both rats and mice. A striking difference in
response between these species is being
observed. The F344 rat develops a rela-
tively high crude incidence and multiplic-
ity oflung tumors. These tumors, however,
essentially lack mutations in genes com-
monly found to be mutated in various
types of human cancers, including lung
cancers. On the other hand, at doses that
induce substantial carcinogenicity in rats,
the carcinogenic response is weak in strain
A mice and absent in strain C3H mice.
Clearly, continued efforts are required to
understand the similarities/differences in
responses of rats versus those in mice, the
molecular events surrounding Be-induced
carcinogenesis, and the responses of these
species to Be-containing compounds other
than Be metal before these findings can be
extrapolated to humans.
In conclusion, ITRI studies are oriented
toward understanding events involved in
the development of beryllium-induced,
immune-mediated, chronic granuloma-
tous lung diseases, and lung cancer. This
research program constitutes an ongoing,
coordinated effort to understand beryl-
lium-induced lung disease in experimental
animal models. Use ofmultiple species in
this program increases the scientific basis
for eventual extrapolation of the results
from laboratory animal models to humans.
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